title: A multicenter, double-blind study to evaluate the efficacy and safety of 2 treatments in participants with mild to moderate acne vulgaris.
abstract: Acne treatment regimens have changed due to the recent over-the-counter (OTC) switch of all prescription benzoyl peroxide (BPO) topical preparations. The elimination of prescription single-agent BPO products means that dermatologists must select from a variety of OTC formulations to utilize the time-tested efficacy of BPO in the treatment of mild to moderate acne. Our research compared the efficacy and safety of an OTC BPO 5.5% formulation with lipohydroxy acid and tretinoin cream 0.025% with prescription clindamycin 1%-BPO 5% gel and tretinoin cream 0.025%. Parity was demonstrated between the 2 treatment regimens at 12 weeks.
authors: Department of Dermatology, Duke University School of Medicine, Durham, North Carolina, USA. zdraelos@northstate.net
authors: Zoe Diana
authors: ZD
authors: Draelos
authors: Alan R
authors: AR
authors: Shalita
authors: Diane
authors: D
authors: Thiboutot
authors: Christian
authors: C
authors: Oresajo
authors: Margarita
authors: M
authors: Yatskayer
authors: Susanna
authors: S
authors: Raab
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy* / Q000473:pathology; D000293:Adolescent; D000328:Adult; D001585:Benzoyl Peroxide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002981:Clindamycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D004366:Nonprescription Drugs / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012459:Salicylates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D055815:Young Adult
chemical_list: C113468:2-hydroxy-5-octanoylbenzoic acid; D003879:Dermatologic Agents; D004338:Drug Combinations; D004366:Nonprescription Drugs; D012459:Salicylates; C466951:clindamycin phosphate benzoyl peroxide combination; D002981:Clindamycin; D014212:Tretinoin; D001585:Benzoyl Peroxide